11-5226592-A-T
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2PP3_StrongPP5
The NM_000518.5(HBB):c.300T>A(p.Asp100Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,854 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000518.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461854Hom.: 0 Cov.: 36 AF XY: 0.00000138 AC XY: 1AN XY: 727232
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Erythrocytosis, familial, 6 Pathogenic:1
The Asp100Glu variant in HBB is a high oxygen affinity hemoglobin described first in members of a Portuguese family. The altered functional properties of this variant likely result from the inability to form a hydrogen bond between beta-chain aa 100Glu and alpha-chain aa 43Tyr; such a bond is formed in deoxy Hb A between the normally occurring beta 100Asp and alpha 43Tyr. The affected members have a distinct erythrocytosis with high hemoglobin levels. -
not specified Uncertain:1
Variant summary: HBB c.300T>A (p.Asp100Glu) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251404 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. The variant, c.300T>A, (also known as Asp99Glu or Hb Coimbra) is a known high oxygen affinity hemoglobin variant, and is reported in several heterozygotes, who were mostly asymptomatic and had compensatory erythrocytosis found in routine blood tests (e.g. Tamagnini_1991, Bento_2013, Oliveira_2018). To our knowledge, no homozygous occurrences or compound heterozygosity with pathogenic HBB variants were reported, therefore no clear conclusions about association of the variant with Hemoglobinopathy can be made. Publications reported experimental evidence evaluating samples from heterozygous carriers, and demonstrated that the variant resulted in an increase in oxygen affinity (Tamagnini_1991, Jorge_2018), but no differences in Bohr effect were found (Jorge_2018). One submitter has provided clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic for Erythrocytosis. Based on the evidence outlined above, the variant was classified as uncertain significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at